Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Solid Tumors and Lymphomas
Interventions: DRUG: Alobresib|DRUG: Exemestane|DRUG: Fulvestrant
Sponsor: Gilead Sciences